Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex [Phase 3]

View source ↗

Summary

Phase 3 study evaluating intravenous sulbactam-ETX2514 for infections caused by Acinetobacter baumannii-calcoaceticus complex has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acinetobacter Baumannii-calcoaceticus Complex Infections
• Bacteremia
• Hospital-acquired Bacterial Pneumonia
• Ventilator-associated Bacterial Pneumonia

Drugs mentioned

• sulbactam-ETX2514

Snippet

Sponsor: Entasis Therapeutics | Conditions: Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia | Phase 3 | Status: COMPLETED | Results posted: 2023-02-01